Treatment with corticosteroids can control mild to moderate emesis during chemotherapy (Cassileth et al., 1983) and adds to the antiemetic effect of high-dose metoclopramide in severe emesis (Bruera et al., 1983) . Moreover, pregnancy induced nausea is more common among women with low than high cortisol excretion (Jarnfelt-Samsioe et al., 1986) . These findings warrant an investigation whether endogenous cortisol secretion is associated with nausea induced by chemotherapy.
Treatment with corticosteroids can control mild to moderate emesis during chemotherapy (Cassileth et al., 1983) and adds to the antiemetic effect of high-dose metoclopramide in severe emesis (Bruera et al., 1983) . Moreover, pregnancy induced nausea is more common among women with low than high cortisol excretion (Jarnfelt-Samsioe et al., 1986) . These findings warrant an investigation whether endogenous cortisol secretion is associated with nausea induced by chemotherapy.
The aim of the present study was to relate endogenous cortisol secretion to individual differences in chemotherapy induced nausea and vomiting. Urinary cortisol excretion remain stable over time, particularly during resting conditions (Forsman & Lundberg, 1982) . Therefore, night time urine was collected to assay cortisol excretion. Self-reports were used to assess nausea and vomiting. The urinary sample was collected from the time of voiding before going to bed until the time of rising, the night before the second chemotherapy course. Urine was collected in a plastic container with sodiumdisulfit as antioxidant. Volume and collection time were noted and the specimens were stored at -18°C until analysed for cortisol by radioimmunoassay with a sensitivity of 3-5 nmol 1' (kits from New England Nuclear Corporation). Cross reactivity for 11-deoxycortisol, corticosterone and 11 -deoxycorticosterone was 15, 2 and 0.5% respectively. Excretion rate was expressed as pmol min-'. Nausea was rated by the patients on a 100 mm visual analog scale (VAS) during and after the second chemotherapy course. A zero score is anchored at the left end with no nausea at all' and a maximum score of 100 denotes 'worst possible nausea'. Vomiting episodes were counted. Self-reports of nausea (VAS) and vomiting were given during (one report) and after (two reports) infusion on the treatment day. Patients also reported their nausea and vomiting every 6th hour for the 2 following days. The daily averages of these values are reported. Vomiting was excluded from further analyses because of its low occurrence.
The median used to form groups high and low in cortisol excretion was 60.5 pmol min-'. The high and low excretion group had an average (s.e.m.) of 107.3 (10.8) and 31.4 (5.7) pmol min-' respectively. Figure 1 shows that the group with high compared to low night-time cortisol excretion experienced significantly less nausea.
Nausea was higher in patients with relatively lower cortisol levels during (t(18) = 2.55; P<.02) and after (t(18) = 3.01; P <.01) the chemotherapy infusion as well as on the first (t(18) = 2.47; <,.02) and second (t (18) (7.0) in young and old patients respectively (t(18) = 1; n.s.). Sex, diagnosis or type of antiemetic or cancer treatment were not different in the 'high' and 'low' cortisol excretion groups (see Table I ). No patient had elevated serum creatinine and six patients had at least one pathological serum liver enzyme.
Liver and kidney functions were unrelated both to cortisol excretion and nausea ratings. Urinary cortisol excretion significantly predicted chemotherapy related nausea. Relatively higher excretion rates were always associated with relatively lower levels of nausea. The predictive power was not secondary to sex, diagnosis, treatment, kidney or liver function. A positive and significant correlation between age and cortisol excretion emerged. Thus, it could be argued that our results do not reflect a causal relation between cortisol excretion and nausea, but that age is associated both with nausea and cortisol excretion, and confounds the association. The mechanism whereby age influences nausea remains, however, unknown (c.f. Andrews et al., 1988) and, in the present study, the association between cortisol excretion and nausea was stronger than the association between age and nausea. Since younger individuals tend to have lower cortisol levels than older persons (Arnetz et al., in press) we suggest that differences in endogenous cortisol secretion is a mechanism partly explaining the age variations in nausea during chemotherapy.
There are several hypotheses explaining an antiemetic effect of cortisol. First, cortisol may reduce cerebral oedema, which is known to be an emetic stimulus (Davis et al., 1986) . Second, it may affect the permeability of the blood-brain barrier and limit the influx of emetic agents to the brain (Davies et al., 1986) . Third, cortisol possibly affects 5-hydroxytryptamine (5-HT) turnover in the central nervous system by shunting the metabolism of tryptophan away from 5-HT pathways (Young, 1981) . We propose that the anti-inflammatory properties of cortisol may act to prevent the release of serotonin in the gut or prevent activation of 5-HT receptors in the gastrointestinal system.
We have demonstrated that endogenous cortisol levels predict acute and delayed nausea during chemotherapy. This supports the study of mechanisms involved in the antiemetic action of cortisol and its use to identify patients in need of intense antiemetic treatment when given chemotherapy with low emetic potential.
